WO2004110979A2 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator - Google Patents
Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator Download PDFInfo
- Publication number
- WO2004110979A2 WO2004110979A2 PCT/EP2004/006318 EP2004006318W WO2004110979A2 WO 2004110979 A2 WO2004110979 A2 WO 2004110979A2 EP 2004006318 W EP2004006318 W EP 2004006318W WO 2004110979 A2 WO2004110979 A2 WO 2004110979A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- cycloalkoxy
- haloalkyl
- Prior art date
Links
- 0 *C(*)(*)CCc1ccc(*)cc1 Chemical compound *C(*)(*)CCc1ccc(*)cc1 0.000 description 2
- WPHGSKGZRAQSGP-UHFFFAOYSA-N C1C2C1CCCC2 Chemical compound C1C2C1CCCC2 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
Definitions
- the present invention relates to amino-propanol derivatives, process for their production, their uses and pharmaceutical compositions containing them.
- R 1 is C 1-6 alkyl; Ci -6 alkyl substituted by hydroxy, C 1-2 alkoxy or 1 to 6 fluorine atoms; C 2 - 6 alkenyl; or C 2-6 alkynyl;
- R 2 is C 1-10 alkyl; C- M ohaloaikyl; C 1-9 alkoxy; C 1-9 haloalkoxy; each optionally substituted on the terminal C atom by phenyl, phenoxy, C 3 . 6 cycloalkyl, C 3-6 cycloalkoxy, heteroaryl, heteroaryloxy, a heterocyclic residue, wherein phenyl, phenoxy, C 3 . 6 cycloalkyl, C 3 .
- cycloalkoxy, heteroaryl, heteroaryloxy, a heterocyclic residue each may be ring- substituted by 1 to 5 substituents selected from hydroxy, halogen, C 1-4 alkyl, C 1- 4 haloalkyl, C 3 . 6 cycloalkyl, Ci. 4 alkoxy, C 1-4 haloalkoxy, C 3 . 6 cycloalkoxy, C ⁇ cycloalkylC ⁇ 2 alkyl, cyano, phenyl, and phenyl substituted by hydroxy, halogen, C 1-4 alkyl, C 1- 4 haloalkyl, C 1-4 alkoxy, or cyan ⁇ ; or a residue of the formula (b)
- R 10 is C 1-6 alkyl
- R 1I is C 1-6 alkyl; C 1-10 haloalkyl; each optionally substituted on the terminal C atom by a phenyl, phenoxy, C 3 . 6 cycloalkyl, C 3-6 cycloalkoxy, heteroaryl, heteroaryloxy, a heterocyclic residue, wherein phenyl, phenoxy, C 3 . 6 cycloalkyl, C 3 . 6 cycloalkoxy, heteroaryl, heteroaryloxy, a heterocyclic residue each may be ring-substituted by 1 to 5 substituents selected from hydroxy, halogen, C 1-4 alkyl, C 1 .
- R 3 is Z-X 2 wherein Z is CH 2 , CHF, CHMe or CF 2 and X 2 is OH or a residue of formula (a) O wherein Z 1 is a direct bond, CH 2 , CHF, CF 2 or O, and each of R 8 and R 9 , independently, is H or Ci -4 alkyl optionally substituted by 1 , 2 or 3 halogen atoms; and each of R 4 and R 5 , independently, is H; Ci -4 alkyl optionally substituted by 1 , 2 or 3 halogen atoms; or acyl
- the two additional substituents are electrophilic substituents.
- the two additional substituents may be identical or different.
- a preferred compound of formula I is
- R 1 to R 5 are as defined above and each of R 6 and R 7 , independently, is hydroxy; halogen; Ci. 4 alkyl; Ci -6 cycloalkyl; Ci. 4 alkoxy;
- R 6 and R 7 are in orf ⁇ o-position to R 2 .
- Alkyl or alkyl moiety may be straight or branched chain.
- Alkenyl may be e.g. vinyl.
- Alkynyl may be e.g. propyn-2-yl.
- Acyl may be a residue R-CO wherein R is C 1-6 alkyl, C 3 . 6 cycloalkyl, phenyl or phenyl C 1-4 alkyl.
- Halogen may be fluorine, chlorine or bromine, preferably fluorine or chlorine. When alkyl is substituted by hydroxy, it is preferably on the terminal carbon atom.
- PhenylC 1-2 alkyl may be e.g. benzyl.
- Haloalkyl may be straight chain or branched alkyl substituted by one or more halogen atoms, preferably fluorine atoms.
- Heteroaryl may be a 5 to 8 membered aromatic ring comprising 1 to 4 heteroatoms selected from N, O and S, e.g. pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thienyl, thia- zolyl, isothiazolyl, pyrrolyl, imidazolyl, or pyrazolyl.
- heterocyclic residue is meant a 3 to 8, preferably 5 to 8, membered saturated or unsaturated heterocyclic ring comprising e.g. tetrahydrofuryl, tetrahydropyranyl, aziridinyl, piperidinyl, pyrrolidinyl, piperazinyl.
- Compounds of formula I may exist in free form or in salt form, e.g. addition salts with e.g. inorganic acids, such as hydrochloride, hydrobromide or sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate or ben- zenesulfonate salts.
- inorganic acids such as hydrochloride, hydrobromide or sulfate
- organic acids such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate or ben- zenesulfonate salts.
- Compounds of formula I and their salts, in hydrate or solvate form are also part of the invention.
- the present invention embraces cis-compounds, trans-compounds and mixtures thereof. Similar considerations apply in relation to starting materials exhibiting asymmetric carbon atoms or unsaturated bonds as mentioned above, e.g. compounds of formula III, IV or V as indicated below.
- R 2 is C 1-7 alkyl or C-
- R 3 is CH 2 -OH or CH 2 -OPO 3 H 2 ;
- each of R 4 and R 5 is hydrogen
- R 6 is methyl, methoxy, trifluoromethyl, chloro, fluoro or bromo;
- R 6 is ortho to R 2 ;
- R 7 is methyl, methoxy, trifluoromethyl, chloro, fluoro or bromo;.
- R 7 is ortho to R 2 . - A -
- the present invention also includes a process for the preparation of compounds of formula 1 which process comprises a) for a compound of formula I wherein R 3 is Z-X 2 , X 2 being OH, removing the protecting group present in a compound of formula III
- R 3 is Z-X 2 wherein X 2 is OH, R' 5 is an amino protecting group, and ring A is as defined above, or b) for a compound of formula I wherein R 3 is Z-X 2 , X 2 being a residue of formula (a), removing the protecting groups present in a compound of formula IV
- each of R' 8 or R' 9 is a hydrolysable or hydrogenolysable group or R' 8 and R' 9 form together a divalent bridging residue optionally fused to a ring (e.g. benzene ring), and, where required, converting the compounds of formula I obtained in free form into the desired salt form, or vice versa.
- a ring e.g. benzene ring
- Process step a) may be carried out in accordance with methods known in the art.
- the removal of the amino protecting groups may conveniently be performed according to methods known in the art, e.g. by hydrolysis, e.g. in an acidic medium, for example using hydrochloric acid.
- Examples of protecting groups for amino groups are e.g. as disclosed in "Protective Groups in Organic Synthesis” T.W. Greene, J.Wiley & Sons NY, 2 nd ed., chapter 7, 1991 , and references therein, e.g.
- benzyl p-methoxybenzyl, methoxymethyl, tetrahydro- pyranyl, trialkylsilyl, acyl, tert.-butoxy-carbonyl, benzyloxycarbonyl, 9-fluorenyl methoxy car- bonyl, trifluoroacetyl, and the like.
- each of R' 8 and R' 9 may have the significance of e.g. tert-butyl, phenyl or benzyl or form together a cyclic system such as in 1 ,5-dihydro-2,4,3-benzodioxa- phosphepin.
- Process step b) may be performed according to methods known in the art, e.g. by hydrolysis, e.g. in a basic medium when R' 6 and R' 7 are each a hydrolysable group, for example using a hydroxide such as barium hydroxide or in an acidic medium when R' 6 and R' 7 are each a tert-butyl group. It may also be performed by hydrogenolysis, e.g. in the presence of a catalyst, e.g. Pd/C, followed by hydrolysis, e.g. in an acidic medium, for example HCI.
- a catalyst e.g. Pd/C
- the present invention also includes a process for the preparation of a compound of formula III which process comprises transforming a compound of formula V
- R 1 , R' 3 , R 4 and R' 5 are as defined above, and ring A is as defined above, to introduce the desired residue -R 2 e.g. by an alkylation.
- Alkylation of the compounds of formula V may be performed according to methods known in the art, e.g. by nucleophilic substitution, e.g. by reaction with an alkylating agent X 3 -R 2 wherein X 3 is mesylate, tosylate, triflate, nosylate, chloride, bromide or iodide.
- the alkylation may also be carried out by following the Mitsunobu protocol using HO-R 2 (e.g.
- the title compound is prepared according to ex. 7 using [(R)-3-(3-Chloro-5-methoxy-4- pentyloxy-phenyl)-1-hydroxymethyl-1-methyl-propyl]-carbamic acid tert-butyl ester as starting material.
- MS (ESI+): m/z 331 (MH + ).
- Example 10 Phosphoric acid mono-((R)-2-amino-4- ⁇ 3-chloro-4-[2-(4-ethoxy-phenyl)- ethoxy]-5-methoxy-phenyl ⁇ -2-methyl-butyl) ester
- EDG-1 SI P 1
- EDG-3 SIP 3
- EDG-5 SI P 2
- EDG-6 SI P 4
- EDG-8 SI P 5
- Functional receptor activation is assessed by quantifying compound induced GTP [ ⁇ - 35 S] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor.
- the assay technology used is SPA (scintillation proximity based assay).
- DMSO dissolved compounds are serially diluted and added to SPA- bead (Amersham-Pharmacia) immobilised S1 P receptor expressing membrane protein (10-20 ⁇ g/well) in the presence of 50 mM Hepes, 100 mM NaCI, 10 mM MgCI 2 , 10 ⁇ M GDP, 0.1% fat free BSA and 0.2 nM GTP [ ⁇ - 35 S] (1200 Ci/mmol).
- unbound GTP [ ⁇ - 35 S] is separated by a centrifugation step.
- Luminescence of SPA beads triggered by membrane bound GTP [ ⁇ - 35 S] is quantified with a TOPcount plate reader (Packard).
- EC 50 S are calculated using standard curve fitting software.
- a compound of formula I or the vehicle is administered orally by gavage to rats.
- Tail blood for hematological monitoring is obtained on day -1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application.
- the compounds of formula I deplete peripheral blood lymphocytes when administered at a dose of 0.03 to 3 mg/kg. For example, following results are obtained: depletion of peripheral blood lymphocytes by more than 50%
- Example 1 0.5 mg/kg p.o. after 6h, >1 mg/kg p.o. after 48h.
- Example 5 0.2 mg/kg p.o. after 6h, >1 mg/kg p.o. after 48h.
- Example 9 0.2 mg/kg p.o. after 6h.
- the compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by lymphocytes interactions, e.g. in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g.
- rheumatoid arthritis systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or Il and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others, allergic diseases, e.g. allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis, inflammatory diseases optionally with underlying aberrant reactions, e.g.
- inflammatory bowel disease Crohn's disease or ulcerative colitis
- intrinsic asthma inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologicaily-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis, ischemia/reperfusion injury, e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock, cancer, e.g.
- T cell lymphomas or T cell leukemias angiogenesis
- infectious diseases e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacterial infection, or senile dementia.
- cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
- the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired.
- An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.
- Suitable unit dosage forms for oral administration comprise from ca. 0.1 to 50 mg active ingredient.
- the compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
- Pharmaceutical compositions comprising a compound of formula I, e.g. of formula II, in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
- the compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form e.g. as indicated above.
- Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
- the present invention further provides:
- a method for preventing or treating disorders or diseases mediated by lymphocytes, e.g. such as indicated above, in a subject in need of such treatment comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
- a method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
- a compound of formula I in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 or 1.2 above.
- a pharmaceutical composition e.g. for use in any of the methods as in 1.1 or 1.2 above comprising a compound of formula I, e.g. of formula II, in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
- a compound of formula I e.g. of formula II, or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any of the method as in 1.1 or 1.2 above.
- the compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent.
- the compounds of formula I e.g. of formula II, may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A, FK 506 or ISA TX 247; a mTOR inhibitor, e.g.
- rapamycin 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841 , TAFA-93, biolimus 7 or biolimus 9; an ascomycin having immunosuppressive properties, e.g. ABT-281 , ASM981 , etc.; a S1 P receptor agaonist e.g.
- FTY720 or an analogue thereof corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40. CD45, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g.
- a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5-fluorouracil; or an anti-infectious agent.
- a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-
- a method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a compound of formula I and at least a second drug substance, e.g. an immunosuppressant, immunomodulatory, anti-inflammatory or chemotherapeutic drug, e.g. as indicated above.
- a second drug substance e.g. an immunosuppressant, immunomodulatory, anti-inflammatory or chemotherapeutic drug, e.g. as indicated above.
- a pharmaceutical combination e.g. a kit, comprising a) a first agent which is a compound of formula I as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent, e.g. an immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious agent.
- the kit may comprise instructions for its administration.
- co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
- pharmaceutical combination as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
- fixed combination means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
- non-fixed combination means that the active ingredients, e.g.
- a compound of formula I and a co- agent are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
- cocktail therapy e.g. the administration of 3 or more active ingredients.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0411294-6A BRPI0411294A (en) | 2003-06-12 | 2004-06-11 | amino propanol derivatives |
MXPA05013348A MXPA05013348A (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator. |
CA002527977A CA2527977A1 (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
ES04739810T ES2384324T3 (en) | 2003-06-12 | 2004-06-11 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
JP2006515899A JP4512592B2 (en) | 2003-06-12 | 2004-06-11 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
AT04739810T ATE549311T1 (en) | 2003-06-12 | 2004-06-11 | AMINO-PROPANOL DERIVATIVES AS MODULATORS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR |
US10/558,690 US7696184B2 (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
EP04739810A EP1636171B1 (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulators |
AU2004247384A AU2004247384B2 (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0313612.4A GB0313612D0 (en) | 2003-06-12 | 2003-06-12 | Organic compounds |
GB0313612.4 | 2003-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004110979A2 true WO2004110979A2 (en) | 2004-12-23 |
WO2004110979A3 WO2004110979A3 (en) | 2005-02-10 |
Family
ID=27589973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/006318 WO2004110979A2 (en) | 2003-06-12 | 2004-06-11 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
Country Status (12)
Country | Link |
---|---|
US (1) | US7696184B2 (en) |
EP (1) | EP1636171B1 (en) |
JP (1) | JP4512592B2 (en) |
CN (1) | CN100358861C (en) |
AT (1) | ATE549311T1 (en) |
AU (1) | AU2004247384B2 (en) |
BR (1) | BRPI0411294A (en) |
CA (1) | CA2527977A1 (en) |
ES (1) | ES2384324T3 (en) |
GB (1) | GB0313612D0 (en) |
MX (1) | MXPA05013348A (en) |
WO (1) | WO2004110979A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006094705A1 (en) * | 2005-03-04 | 2006-09-14 | Novartis Ag | Ophthalmic uses of s1p receptor modulators |
WO2007069712A1 (en) * | 2005-12-15 | 2007-06-21 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
US7241812B2 (en) | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
WO2008018447A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
WO2008018427A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
US8129361B2 (en) | 2007-06-14 | 2012-03-06 | Mitsubishi Tanabe Pharma Corporation | Amine compound and pharmaceutical use thereof |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US8853419B2 (en) | 2010-01-27 | 2014-10-07 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324210D0 (en) | 2003-10-15 | 2003-11-19 | Novartis Ag | Organic compounds |
PL1772145T3 (en) * | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Method of effectively using medicine and method concerning prevention of side effect |
PT2511262T (en) * | 2004-10-12 | 2017-03-30 | Kyorin Seiyaku Kk | Process for producing 2-amino-2-[2-[4-(3-benzyloxyâphenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride |
PL1919290T3 (en) * | 2005-07-12 | 2014-06-30 | Ampio Pharmaceuticals Inc | Methods and products for treatment of diseases |
KR101297302B1 (en) * | 2005-10-07 | 2013-08-19 | 교린 세이야꾸 가부시키 가이샤 | Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient and therapeutic method for liver disease |
TWI389683B (en) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
JP5452237B2 (en) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | Therapeutic or prophylactic agent for inflammatory bowel disease comprising an amino alcohol derivative as an active ingredient |
MX2011013984A (en) | 2009-06-22 | 2012-06-01 | Dmi Acquisition Corp | Methods and products for treatment of diseases. |
WO2010151530A1 (en) | 2009-06-22 | 2010-12-29 | Dmi Acquisition Corp. | Method for treatment of diseases |
CN102565253A (en) * | 2010-12-16 | 2012-07-11 | 中国人民解放军第二军医大学 | Micromolecular metabolite atlas as well as producing method and application thereof |
KR101889131B1 (en) * | 2011-12-23 | 2018-09-20 | 메이지 세이카 파루마 가부시키가이샤 | Novel s1p receptor modulator |
BR112015014261A8 (en) | 2012-12-19 | 2019-10-08 | Ampio Pharmaceuticals Inc | danazol compound, its use and pharmaceutical formulation comprising this |
KR20210074291A (en) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | Compounds useful for the treatment of autoimmune and inflammatory disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076995A2 (en) * | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US5948820A (en) * | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
KR100358922B1 (en) * | 1994-08-22 | 2003-01-24 | 미쯔비시 웰 파마 가부시키가이샤 | Benzene compound and medicinal use thereof |
IL151108A0 (en) | 2000-02-11 | 2003-04-10 | Res Dev Foundation | Tocopherols, tocotrienols, other chroman and chain derivatives and uses thereof |
EP1622860B1 (en) * | 2003-04-30 | 2012-02-29 | Novartis AG | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs |
-
2003
- 2003-06-12 GB GBGB0313612.4A patent/GB0313612D0/en not_active Ceased
-
2004
- 2004-06-11 AU AU2004247384A patent/AU2004247384B2/en not_active Ceased
- 2004-06-11 MX MXPA05013348A patent/MXPA05013348A/en active IP Right Grant
- 2004-06-11 JP JP2006515899A patent/JP4512592B2/en not_active Expired - Fee Related
- 2004-06-11 BR BRPI0411294-6A patent/BRPI0411294A/en not_active IP Right Cessation
- 2004-06-11 AT AT04739810T patent/ATE549311T1/en active
- 2004-06-11 EP EP04739810A patent/EP1636171B1/en not_active Not-in-force
- 2004-06-11 CN CNB2004800152297A patent/CN100358861C/en not_active Expired - Fee Related
- 2004-06-11 ES ES04739810T patent/ES2384324T3/en active Active
- 2004-06-11 US US10/558,690 patent/US7696184B2/en not_active Expired - Fee Related
- 2004-06-11 WO PCT/EP2004/006318 patent/WO2004110979A2/en active Application Filing
- 2004-06-11 CA CA002527977A patent/CA2527977A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076995A2 (en) * | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7241812B2 (en) | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
JP2008531632A (en) * | 2005-03-04 | 2008-08-14 | ノバルティス アクチエンゲゼルシャフト | Ophthalmic use of S1P receptor modulators |
WO2006094705A1 (en) * | 2005-03-04 | 2006-09-14 | Novartis Ag | Ophthalmic uses of s1p receptor modulators |
JP2013063991A (en) * | 2005-03-04 | 2013-04-11 | Novartis Ag | Ophthalmic use of s1p receptor modulator |
AU2010202185B2 (en) * | 2005-03-04 | 2012-06-14 | Novartis Ag | Ophthalmic uses of S1P receptor modulators |
US8809304B2 (en) | 2005-12-15 | 2014-08-19 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
JP4833998B2 (en) * | 2005-12-15 | 2011-12-07 | 田辺三菱製薬株式会社 | Amine compounds and their pharmaceutical uses |
TWI451865B (en) * | 2005-12-15 | 2014-09-11 | Mitsubishi Tanabe Pharma Corp | Amine compound and its medical use |
WO2007069712A1 (en) * | 2005-12-15 | 2007-06-21 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
WO2008018427A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
WO2008018447A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
US8129361B2 (en) | 2007-06-14 | 2012-03-06 | Mitsubishi Tanabe Pharma Corporation | Amine compound and pharmaceutical use thereof |
US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9126932B2 (en) | 2008-07-23 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9522133B2 (en) | 2008-07-23 | 2016-12-20 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US9108969B2 (en) | 2008-08-27 | 2015-08-18 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8853419B2 (en) | 2010-01-27 | 2014-10-07 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US11149292B2 (en) | 2010-01-27 | 2021-10-19 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US9447041B2 (en) | 2010-01-27 | 2016-09-20 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US11674163B2 (en) | 2010-01-27 | 2023-06-13 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US9175320B2 (en) | 2010-01-27 | 2015-11-03 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
US11896578B2 (en) | 2015-01-06 | 2024-02-13 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11091435B2 (en) | 2015-06-22 | 2021-08-17 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
US10676435B2 (en) | 2015-06-22 | 2020-06-09 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
Also Published As
Publication number | Publication date |
---|---|
AU2004247384A1 (en) | 2004-12-23 |
WO2004110979A3 (en) | 2005-02-10 |
CA2527977A1 (en) | 2004-12-23 |
CN1798728A (en) | 2006-07-05 |
GB0313612D0 (en) | 2003-07-16 |
JP4512592B2 (en) | 2010-07-28 |
US20070010494A1 (en) | 2007-01-11 |
US7696184B2 (en) | 2010-04-13 |
CN100358861C (en) | 2008-01-02 |
AU2004247384B2 (en) | 2008-02-28 |
EP1636171B1 (en) | 2012-03-14 |
JP2006527231A (en) | 2006-11-30 |
EP1636171A2 (en) | 2006-03-22 |
ATE549311T1 (en) | 2012-03-15 |
MXPA05013348A (en) | 2006-03-09 |
ES2384324T3 (en) | 2012-07-03 |
BRPI0411294A (en) | 2006-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004247384B2 (en) | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | |
EP1622860B1 (en) | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs | |
EP1622866B1 (en) | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | |
EP1753712B1 (en) | Amino-propanol derivatives | |
US7728020B2 (en) | Amino acid derivatives | |
US20040147490A1 (en) | 2-Amino-propanol derivatives | |
WO2004024673A1 (en) | Amino-propanol derivatives | |
AU2002257719A1 (en) | 2-amino-propanol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004739810 Country of ref document: EP Ref document number: 2007010494 Country of ref document: US Ref document number: 10558690 Country of ref document: US Ref document number: 2004247384 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2527977 Country of ref document: CA Ref document number: 20048152297 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/013348 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006515899 Country of ref document: JP Ref document number: 3354/CHENP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004247384 Country of ref document: AU Date of ref document: 20040611 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004247384 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739810 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0411294 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10558690 Country of ref document: US |